Observed numbers and observed/expected ratios of solid tumors among 16 367 of the 2-month survivors of chronic lymphocytic leukemia reported to the SEER Program between 1973 and 1996
| . | All patients (n = 16 367) . | Men (n = 9517) . | Women (n = 6850) . | |||
|---|---|---|---|---|---|---|
| Obs . | O/E . | Obs . | O/E . | Obs . | O/E . | |
| All solid tumors* | 1820 | 1.20 | 1210 | 1.22† | 610 | 1.18† |
| Specific sites | ||||||
| All buccal | 42 | 1.02 | 35 | 1.13 | 7 | 0.71 |
| Esophagus | 14 | 0.80 | 14 | 1.02 | 0 | [E] = 3.8 |
| Stomach | 47 | 1.10 | 24 | 0.81 | 23‡ | 1.76† |
| Colon | 206 | 1.13 | 110 | 1.01 | 96 | 1.23 |
| Rectum | 72 | 1.09 | 40 | 0.93 | 32 | 1.38 |
| Liver, bile duct, gall bladder | 19 | 0.73 | 11 | 0.68 | 8 | 0.80 |
| Pancreas | 45 | 0.96 | 32 | 1.19 | 13 | 0.65 |
| Larynx | 31 | 1.72† | 27 | 1.68† | 4 | 1.98 |
| Lung | 421 | 1.66† | 318 | 1.68† | 103 | 1.62† |
| Female breast | 141 | 0.97 | — | — | 141 | 0.97 |
| Uterine cervix | 4 | 0.56 | — | — | 4 | 0.56 |
| Uterine corpus | 23 | 0.68 | — | — | 23 | 0.69 |
| Ovary | 18 | 0.92 | — | — | 18 | 0.92 |
| Prostate | 338 | 1.01 | 338 | 1.01 | — | — |
| Testis | 2 | 2.44 | 2 | 2.44 | — | — |
| Bladder | 91 | 0.98 | 64 | 0.85 | 27 | 1.52† |
| Kidney, renal pelvis, ureter | 42 | 1.16 | 29 | 1.12 | 13 | 1.24 |
| Melanoma | 90 | 3.18† | 62 | 3.14† | 28 | 3.28† |
| Eye | 5 | 2.26 | 3 | 2.10 | 2 | 2.56 |
| Brain, central nervous system | 221-153 | 1.49 | 18 | 1.91† | 4 | 0.76 |
| Thyroid | 4 | 0.60 | 3 | 0.98 | 1 | 0.28 |
| Kaposi sarcoma1-155 | 9 | 5.09† | 3 | 2.06 | 6 | 19.13† |
| Other1-154 | 134 | 1.44† | 77 | 1.45† | 57 | 1.44† |
| . | All patients (n = 16 367) . | Men (n = 9517) . | Women (n = 6850) . | |||
|---|---|---|---|---|---|---|
| Obs . | O/E . | Obs . | O/E . | Obs . | O/E . | |
| All solid tumors* | 1820 | 1.20 | 1210 | 1.22† | 610 | 1.18† |
| Specific sites | ||||||
| All buccal | 42 | 1.02 | 35 | 1.13 | 7 | 0.71 |
| Esophagus | 14 | 0.80 | 14 | 1.02 | 0 | [E] = 3.8 |
| Stomach | 47 | 1.10 | 24 | 0.81 | 23‡ | 1.76† |
| Colon | 206 | 1.13 | 110 | 1.01 | 96 | 1.23 |
| Rectum | 72 | 1.09 | 40 | 0.93 | 32 | 1.38 |
| Liver, bile duct, gall bladder | 19 | 0.73 | 11 | 0.68 | 8 | 0.80 |
| Pancreas | 45 | 0.96 | 32 | 1.19 | 13 | 0.65 |
| Larynx | 31 | 1.72† | 27 | 1.68† | 4 | 1.98 |
| Lung | 421 | 1.66† | 318 | 1.68† | 103 | 1.62† |
| Female breast | 141 | 0.97 | — | — | 141 | 0.97 |
| Uterine cervix | 4 | 0.56 | — | — | 4 | 0.56 |
| Uterine corpus | 23 | 0.68 | — | — | 23 | 0.69 |
| Ovary | 18 | 0.92 | — | — | 18 | 0.92 |
| Prostate | 338 | 1.01 | 338 | 1.01 | — | — |
| Testis | 2 | 2.44 | 2 | 2.44 | — | — |
| Bladder | 91 | 0.98 | 64 | 0.85 | 27 | 1.52† |
| Kidney, renal pelvis, ureter | 42 | 1.16 | 29 | 1.12 | 13 | 1.24 |
| Melanoma | 90 | 3.18† | 62 | 3.14† | 28 | 3.28† |
| Eye | 5 | 2.26 | 3 | 2.10 | 2 | 2.56 |
| Brain, central nervous system | 221-153 | 1.49 | 18 | 1.91† | 4 | 0.76 |
| Thyroid | 4 | 0.60 | 3 | 0.98 | 1 | 0.28 |
| Kaposi sarcoma1-155 | 9 | 5.09† | 3 | 2.06 | 6 | 19.13† |
| Other1-154 | 134 | 1.44† | 77 | 1.45† | 57 | 1.44† |
Person-years of observation were 84 667 for all patients, 46 997 for men, and 37 670 for women.
SEER indicates Surveillance, Epidemiology, and End Results; Obs, observed; O/E, observed/expected; [E], expected number of cases.
Excludes nonmelanoma skin cancers and lymphohematopoietic malignancies.
P < .05.
Includes cancers of antrum (4), cardia (4), greater and lesser curvatures (2), pylorus (2), fundus (1), overlapping lesion (3), and not otherwise specified (7). Histologic types include adenocarcinoma (21), signet cell carcinoma (1), and carcinoid tumor (1).
Includes glioblastoma (16), meningioma (3), astrocytoma (2), and glioma (1).
Absolute excesses of Kaposi sarcoma per 100 000 patients with CLL per year were 15 and 3 for women and men respectively.
Includes 80 cancers of ill-defined or unknown primary site.